Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Apr 5

PMID 33815368

Citations 20

Authors

Massimo Caracciolo

Pierpaolo Correale

Carmelo Mangano

Giuseppe Foti

Carmela Falcone

Sebastiano Macheda

Maria Cuzzola

Marco Conte

Antonella Consuelo Falzea

Eleonora Iuliano

Antonella Morabito

Michele Caraglia

Nicola Polimeni

Anna Ferrarelli

Demetrio Labate

Marco Tescione

Laura Di Renzo

Gaetano Chiricolo

Lorenzo Romano

Antonino De Lorenzo

Affiliations

Soon will be listed here.

Abstract

Lack of specific antiviral treatment for COVID-19 has resulted in long hospitalizations and high mortality rate. By harnessing the regulatory effects of adenosine on inflammatory mediators, we have instituted a new therapeutic treatment with inhaled adenosine in COVID-19 patients, with the aim of reducing inflammation, the onset of cytokine storm, and therefore to improve prognosis. The use of inhaled adenosine in COVID19 patients has allowed reduction of length of stay, on average 6 days. This result is strengthened by the decrease in SARS-CoV-2 positive days. In treated patients compared to control, a clear improvement in PaO/FiO was observed together with a reduction in inflammation parameters, such as the decrease of CRP level. Furthermore, the efficacy of inhaled exogenous adenosine led to an improvement of the prognosis indices, NLR and PLR. The treatment seems to be safe and modulates the immune system, allowing an effective response against the viral infection progression, reducing length of stay and inflammation parameters.

Citing Articles

Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS.

Atif M, Alsrhani A, Naz F, Ullah S, Abdalla A, Ullah M Mol Biol Rep. 2024; 51(1):894.

PMID: 39115571 DOI: 10.1007/s11033-024-09839-1.

Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.

Shafaghat Z, Ghomi A, Khorramdelazad H, Safari E Inflammopharmacology. 2023; 31(6):3005-3020.

PMID: 37805959 DOI: 10.1007/s10787-023-01344-4.

An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds.

Schake P, Dishnica K, Kaiser F, Leberecht C, Haupt V, Schroeder M Sci Rep. 2023; 13(1):9204.

PMID: 37280244 PMC: 10243268. DOI: 10.1038/s41598-023-35671-x.

A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.

Korb V, Schultz I, Beckenkamp L, Wink M Int J Mol Sci. 2023; 24(9).

PMID: 37175571 PMC: 10178215. DOI: 10.3390/ijms24097865.

Safety of Adenosine for the Treatment of Supraventricular Tachycardia in Hospitalized Patients with COVID-19 Pneumonia.

Zivan T, Ruiz R, Martinez A, Pavri B J Clin Med. 2023; 12(3).

PMID: 36769617 PMC: 9917992. DOI: 10.3390/jcm12030969.

References

Le T, Berg N, Harting M, Li X, Eltzschig H, Yuan X . Purinergic Signaling in Pulmonary Inflammation. Front Immunol. 2019; 10:1633. PMC: 6646739. DOI: 10.3389/fimmu.2019.01633. View

Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler H, Schlosser H, Schlaak M . Cytokine release syndrome. J Immunother Cancer. 2018; 6(1):56. PMC: 6003181. DOI: 10.1186/s40425-018-0343-9. View

Reid P, Watt A, Routledge P, Smith A . Intravenous infusion of adenosine but not inosine stimulates respiration in man. Br J Clin Pharmacol. 1987; 23(3):331-8. PMC: 1386232. DOI: 10.1111/j.1365-2125.1987.tb03053.x. View

Michot J, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F . Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol. 2020; 31(7):961-964. PMC: 7136869. DOI: 10.1016/j.annonc.2020.03.300. View

Yaar R, Jones M, Chen J, Ravid K . Animal models for the study of adenosine receptor function. J Cell Physiol. 2004; 202(1):9-20. DOI: 10.1002/jcp.20138. View

Aggarwal N, DAlessio F, Eto Y, Chau E, Avalos C, Waickman A . Macrophage A2A adenosinergic receptor modulates oxygen-induced augmentation of murine lung injury. Am J Respir Cell Mol Biol. 2013; 48(5):635-46. PMC: 3707379. DOI: 10.1165/rcmb.2012-0351OC. View

Bouma M, Jeunhomme T, Boyle D, Dentener M, Voitenok N, van den Wildenberg F . Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. J Immunol. 1997; 158(11):5400-8. View

Fowler R, Lapinsky S, Hallett D, Detsky A, Sibbald W, Slutsky A . Critically ill patients with severe acute respiratory syndrome. JAMA. 2003; 290(3):367-73. DOI: 10.1001/jama.290.3.367. View

Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q . Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia. Gastroenterology. 2020; 159(1):367-370. PMC: 7118654. DOI: 10.1053/j.gastro.2020.03.055. View

10.

Gessi S, Varani K, Merighi S, Leung E, Mac Lennan S, Baraldi P . Novel selective antagonist radioligands for the pharmacological study of A(2B) adenosine receptors. Purinergic Signal. 2008; 2(4):583-8. PMC: 2096665. DOI: 10.1007/s11302-006-9019-x. View

11.

Amisten S, Braun O, Bengtsson A, Erlinge D . Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res. 2007; 122(1):47-57. DOI: 10.1016/j.thromres.2007.08.014. View

12.

Romano L, Marchetti M, Gualtieri P, Di Renzo L, Belcastro M, De Santis G . Effects of a Personalized VLCKD on Body Composition and Resting Energy Expenditure in the Reversal of Diabetes to Prevent Complications. Nutrients. 2019; 11(7). PMC: 6683248. DOI: 10.3390/nu11071526. View

13.

Hasko G, Pacher P . Regulation of macrophage function by adenosine. Arterioscler Thromb Vasc Biol. 2012; 32(4):865-9. PMC: 3387535. DOI: 10.1161/ATVBAHA.111.226852. View

14.

Abouelkhair M . Targeting adenosinergic pathway and adenosine A receptor signaling for the treatment of COVID-19: A hypothesis. Med Hypotheses. 2020; 144:110012. PMC: 7303042. DOI: 10.1016/j.mehy.2020.110012. View

15.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

16.

Huang X, Wei F, Hu L, Wen L, Chen K . Epidemiology and Clinical Characteristics of COVID-19. Arch Iran Med. 2020; 23(4):268-271. DOI: 10.34172/aim.2020.09. View

17.

Rabby M . Current Drugs with Potential for Treatment of COVID-19: A Literature Review. J Pharm Pharm Sci. 2020; 23(1):58-64. DOI: 10.18433/jpps31002. View

18.

Yang J, Lin S, Ji X, Guo L . Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2009; 47(3):193-9. PMC: 7088164. DOI: 10.1007/s00592-009-0109-4. View

19.

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F . Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020; 19(7):102568. PMC: 7252115. DOI: 10.1016/j.autrev.2020.102568. View

20.

Qin B, Ma N, Tang Q, Wei T, Yang M, Fu H . Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol. 2015; 26(3):372-6. DOI: 10.3109/14397595.2015.1091136. View